Hutchison China MediTech Limited

28.95-0.3000-1.03%Vol 49.96K1Y Perf 51.28%
Apr 19th, 2021 12:00 DELAYED
BID28.76 ASK28.97
Open29.05 Previous Close29.25
Pre-Market- After-Market-
 - -%  - -
Target Price
41.10 
Analyst Rating
Strong Buy 1.00
Potential %
42.41 
Finscreener Ranking
★★ —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     50.82
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     44.91
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap4.22B 
Earnings Rating
Neutral
Price Range Ratio 52W %
57.00 
Earnings Date
4th Mar 2021

Today's Price Range

28.3429.05

52W Range

18.2837.00

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Sell
Performance
1 Week
0.03%
1 Month
0.45%
3 Months
-13.51%
6 Months
-7.82%
1 Year
51.28%
3 Years
-10.36%
5 Years
116.99%
10 Years
-

TickerPriceChg.Chg.%
HCM28.95-0.3000-1.03
AAPL134.320.16000.12
GOOG2 296.74-1.0200-0.04
MSFT258.83-1.9100-0.73
XOM56.23-0.4300-0.76
WFC44.060.22000.50
JNJ162.860.62000.38
FB302.37-3.8100-1.24
GE13.36-0.0300-0.22
JPM153.15-0.1500-0.10
Financial StrengthValueIndustryS&P 500US Markets
2.70
3.40
0.06
0.07
-139.60
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
17.30
-69.80
-67.20
-26.20
-50.67
RevenueValueIndustryS&P 500US Markets
205.40M
1.41
-10.95
8.09
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
12/2016 QR-0.060.00-
12/2016 QR-0.0678.57Positive
12/2021 FY-1.73-86.02Negative
12/2022 FY-1.54-65.59Negative
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume49.96K
Shares Outstanding145.62M
Trades Count359
Dollar Volume8.24M
Avg. Volume232.43K
Avg. Weekly Volume135.95K
Avg. Monthly Volume146.41K
Avg. Quarterly Volume227.82K

Hutchison China MediTech Limited (NASDAQ: HCM) stock closed at 29.25 per share at the end of the most recent trading day (a -0.44% change compared to the prior day closing price) with a volume of 126.54K shares and market capitalization of 4.22B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 853 people. Hutchison China MediTech Limited CEO is Christian Hogg.

The one-year performance of Hutchison China MediTech Limited stock is 51.28%, while year-to-date (YTD) performance is -8.65%. HCM stock has a five-year performance of 116.99%. Its 52-week range is between 18.28 and 37, which gives HCM stock a 52-week price range ratio of 57.00%

Hutchison China MediTech Limited currently has a PE ratio of -31.50, a price-to-book (PB) ratio of 8.42, a price-to-sale (PS) ratio of 20.77, a price to cashflow ratio of 5 143.20, a PEG ratio of 2.32, a ROA of -20.44%, a ROC of -30.23% and a ROE of -31.52%. The company’s profit margin is -50.67%, its EBITDA margin is -67.20%, and its revenue ttm is $205.40 Million , which makes it $1.41 revenue per share.

Of the last four earnings reports from Hutchison China MediTech Limited, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Hutchison China MediTech Limited’s next earnings report date is -.

The consensus rating of Wall Street analysts for Hutchison China MediTech Limited is Strong Buy (1), with a target price of $41.1, which is +42.41% compared to the current price. The earnings rating for Hutchison China MediTech Limited stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Hutchison China MediTech Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Hutchison China MediTech Limited has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.16, ATR14 : 1.60, CCI20 : 90.18, Chaikin Money Flow : 0.17, MACD : -1.09, Money Flow Index : 66.76, ROC : 4.20, RSI : 37.49, STOCH (14,3) : 79.42, STOCH RSI : 0.59, UO : 64.48, Williams %R : -20.58), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Hutchison China MediTech Limited in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Hutchison China MediTech Limited

Hutchison China Meditech is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs.

CEO: Christian Hogg

Telephone: +852 21218200

Address: 2 Queen's Road Central, Hong Kong , , HK

Number of employees: 853

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

47%53%

Bearish Bullish

67%33%

News

Stocktwits